Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies Generic Drugs

Multiple Molecules See UK Prices Double In March

Pricewatch UK – March 2021

  • Data

Executive Summary

Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.

You may also be interested in...



Etoricoxib Leads Biggest UK Price Rises In April

Etoricoxib led the steepest price rises for UK generics in April, with the non-steroidal anti-inflammatory drug seeing average prices almost double.

Olmesartan Prices Treble In UK

Average UK trade prices of olmesartan as much as trebled across multiple presentations in the second month of 2021. However, this was not the only triple-digit price rise seen during February, WaveData reveals.

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount

Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies Generic Drugs
Latest Headlines

HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount

PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates

Sandoz Gets EU Nod For Higher-Strength Adalimumab

See All
UsernamePublicRestriction

Register

GB150832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By